Hvilken er prisen på Citius Pharmaceuticals, Inc. (CTXR)

Prisen på Citius Pharmaceuticals, Inc. (CTXR) er $0.5682

Hva er markedsverdien på Citius Pharmaceuticals, Inc. (CTXR)

Markedsverdien på Citius Pharmaceuticals, Inc. (CTXR) er $6.35M

Citius Pharmaceuticals, Inc. (CTXR) Utbytteavkastning

Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. The company is actively advancing five unique products within its pipeline: Mino-Lok: An antibiotic lock solution designed to combat catheter-related bloodstream infections by salvaging the infected central venous catheter. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS). I/ONTAK: An engineered fusion protein, combining IL-2 and diphtheria toxin, purposed for the treatment of patients experiencing persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

År	Utbytteavkastning	Endre
Ikke nok data for de angitte datoene.

År

Utbytteavkastning

Endre

Ikke nok data for de angitte datoene.

Selskap	Utbytteavkastning	Land
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
Lonza Group AG LONN.SW	0.00%	CH
Samsung Biologics Co.,Ltd. 207940.KS	0.00%	KR
UCB S.A. UCB.BR	0.48%	BE

Selskap

Utbytteavkastning

Land